G&S Capital LLC Sells 82 Shares of Johnson & Johnson (NYSE:JNJ)

G&S Capital LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 1.6% during the first quarter, Holdings Channel reports. The firm owned 4,926 shares of the company’s stock after selling 82 shares during the period. G&S Capital LLC’s holdings in Johnson & Johnson were worth $817,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $29,000. Conquis Financial LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $33,000. Bernard Wealth Management Corp. acquired a new stake in Johnson & Johnson in the fourth quarter valued at about $36,000. Finally, Highline Wealth Partners LLC raised its stake in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after acquiring an additional 86 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $155.59 on Thursday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The business’s 50 day simple moving average is $153.63 and its 200 day simple moving average is $153.88. The stock has a market capitalization of $374.36 billion, a PE ratio of 17.31, a PEG ratio of 2.36 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The company had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. As a group, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.34%. Johnson & Johnson’s dividend payout ratio (DPR) is 57.84%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research analyst reports. Raymond James Financial reduced their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research note on Monday, April 14th. Wall Street Zen raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 21st. Leerink Partnrs cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Royal Bank Of Canada reissued an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. Finally, Benchmark raised Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.